Oxford Immunotec

Seventeen of the 25 companies in the 360Dx Index saw their shares decline last month. Invitae paced the decliners, while GenMark led the gainers.

Despite the FDA approval, Oxford Immunotec could still exit the business of blood screening for babesia, one analyst said.

Prompted by an FDA letter requesting additional clinical testing, the firm expects to shut down its development of a babesia blood-donor screening assay.

The new recommendation is a positive for Qiagen and Oxford Immunotec, both of which market interferon gamma-release assays.

US civil surgeons screening immigrants for TB will need to perform an IGRA from Qiagen or Oxford Immunotec, instead of the decades-old tuberculin skin test.

Leading the gainers in the 360 Index was GenMark, whose stock price was up 30 percent last month. Invitae led the decliners as its share price fell 24 percent.

The firm expects full-year revenue of between $103 and $103.5 million, compared to a prior guidance of $103.5 to $104.5 million.

The agreement includes a $27.5 million payment to Oxford, a royalty-free license to Qiagen, and dismissal of all pending litigation.